Oncology Drugs
The Latest
-
Genor Biopharma Says It Will Make Cheaper Breast Cancer Drugs Than Competitors
Genor Biopharma's drug will compete with offerings from Swiss biotechnology company Roche and Britain's GSK. 
Genor Biopharma's drug will compete with offerings from Swiss biotechnology company Roche and Britain's GSK. -
Chinese Biotech Firm Akesobio Successfully Launches $330 Million Hong Kong IPO
Akesobio's 15.95 million shares made available to Hong Kong investors were oversubscribed 639 times during its debut. 
Akesobio's 15.95 million shares made available to Hong Kong investors were oversubscribed 639 times during its debut. -
Cancer Drug Developed By Chinese Biotech BeiGene Gets Green Light
BeiGene's anti-PD-1 antibody immunotherapy tislelizumab received regulatory approval to treat advanced or metastatic urothelial carcinoma. 
BeiGene's anti-PD-1 antibody immunotherapy tislelizumab received regulatory approval to treat advanced or metastatic urothelial carcinoma. -
Gilead Sciences To Buy Cancer Treatment Firm Forty Seven In $4.9 Billion Deal
The acquisition will give Gilead access to Forty Seven's lead cancer drug called Magrolimab, which is supposedly able to turn off a tumor cell's CD47 signals. 
The acquisition will give Gilead access to Forty Seven's lead cancer drug called Magrolimab, which is supposedly able to turn off a tumor cell's CD47 signals. -
Merck To Spin-Off Businesses To Focus More On Growth Drivers
Merck & Co will be spinning off its other businesses, including its women's health and biosimilar drug units, into separate publicly-listed companies. 
Merck & Co will be spinning off its other businesses, including its women's health and biosimilar drug units, into separate publicly-listed companies.
